In Fall 2018, CAPA provided patient input to a proposed protocol by CADTH requiring triple csDMARD therapy for treating moderate to severe rheumatoid arthritis.  To provide a more complete response, CAPA worked collaboratively to provide a joint response on the proposed protocol with the Canadian Rheumatology Association, the Ontario Rheumatology Association and The Arthritis Society.